

**CSRC/DIA Think Tank:  
Enabling Social Listening for Cardiac Safety**

**FDA White Oak  
June 3, 2016**

**Overview:** Postmarketing safety surveillance primarily relies on data from spontaneous adverse event reports, medical literature, and observational databases. Potential limitations of these data sources include potential underreporting, lack of geographic diversity, potential of patients' perspectives being filtered through health care professionals and regulatory agencies, and time lag between event occurrence and discovery.

There is growing interest by safety stakeholders in exploring the use of social media ("social listening") to supplement established approaches for pharmacovigilance. Health information posted online by patients is often publicly available, and thus represents an untapped source of postmarketing safety data that could supplement data from existing sources of cardiac safety information. The purpose of this think tank is to explore current methods of collecting and evaluating social listening data. Representatives from industry, academia, and the FDA will share their perspectives on the topic of social listening and discuss its potential implications in the field of cardiac safety.

---

**8:30 am -9:00 am: Welcome and Introductions**

**CSRC Introduction**  
John Finkle, GSK

**DIA Introduction**  
Raleigh Malik, DIA

**Overview of key concepts**  
Greg Powell, GSK

**9:00 am – 10:25 am: Session 1**

***Review of current safety surveillance methods and overview of social listening***

Session chairs: Greg Powell, GSK  
Harry Seifert, GSK

**Review current safety surveillance methods** (Oanh Dang, FDA)

**Overview of social listening methods** (Nabarun Dasgupta, Epidemico)

**Practical examples of social listening for safety** (Lorrie Schifano, GSK)

**Social listening for cardiac safety research** (Bruce Donzanti, Genentech)

**Panel Discussion**

**10:25 am – 10:35 am: Break**

**10:35 am – 12:00 pm: Session 2**

***Practical considerations of social listening for cardiac safety – why this is valuable***

Session chair: *Melissa Truffa, Abbvie*

**Patient perspective** (Sally Okun- PatientsLikeMe)

**Regulatory perspective MHRA** (Phil Tregunno, MHRA)

**Regulatory perspective FDA** (speaker TBD)

**Pharma perspective** (Mondira Bhattacharya- AbbVie)

**Panel Discussion**

**CSRC/DIA Think Tank:  
Enabling Social Listening for Cardiac Safety**

**FDA White Oak  
June 3, 2016**

**12:00 pm- 12:45 pm**            **Lunch**

**12:45 pm – 2:10 pm:**        **Session 3**

***What evidence is needed to inform use of social listening for cardiac safety***

*Session chair: John van Stekelenborg, Janssen*

**Social Media-people sharing** CV experiences (Amir Lewkowics, Inspire)

**Academia point of view** (Mitchell Krucoff, Duke Clinical Research Institute)

**Cardiac risk factors** (Kevin Campbell, UNC)

**Industry point of view** (John van Stekelenborg, Janssen)

**Panel Discussion**

**2:10 pm – 2:30 pm:**        **Closing remarks**  
*Harry Seifert, GSK*